October 3, 2016
On Thursday, September 22, FDA issued a guidance document, entitled “Self-Identification of Generic Drug Facilities, Sites, and Organizations.” The document was published with the intention of providing generic drug facilities, sites, and organizations with assistance concerning how to comply with the self-identification requirements.
On July 9, 2012, the Generic Drug User Fee Amendments of 2012 (GDUFA) was signed into law with the goals of speeding “the delivery of safe and effective generic drugs to the public and reduce costs to industry.” In order to do this, GDUFA enables the FDA to collect user fees that are used to support critical and measurable enhancements to FDA’s generic drug program. Among a number of other requirements, GDUFA also mandates generic drug facilities, sites, and organizations to self-identify with FDA and to electronically update this identification information on an annual basis.
Self-identification provides the FDA with an abundance of information, enabling quick, accurate, and reliable surveillance when it comes to the inspection and compliance of generic drugs and their facilities. In its guidance document, FDA states that self-identification is required for the following reasons:
Most facilities that are required to self-identify are also required to pay an annual facility user fee, which includes “facilities manufacturing, or intending to manufacture, API of human generic drugs and/or finished dosage form (FDF) human generic drugs.” There are also a number of site and organizations that are required to self-identify, but are not subject the annual facility fee. These include:
According to GDUFA’s requirements, the following types of generic drug facilities, sites, and organizations are required to self-identify with the Agency:
A D-U-N-S number is “a unique nine-digit sequence provided by Dun & Bradstreet.” This number is specific to each site, and each distinct physical location (e.g. branch, division, and headquarter) is assigned a different D-U-N-S number.
FDA requires D-U-N-S numbers “for both the facility or site and the registrant owner of the facility or site if the facility or site is in a different location than the registrant owner location.” The FDA states that the D-U-N-S number is required to help the Agency uniquely identify the registrant as well as each of the organization’s physical locations. In addition, the guidance notes that “the site-specific D-U-N-S number is a widely recognized business identification tool and serves as a useful resource for FDA in identifying and verifying certain business information submitted by a user.”
If the facility or site and/or registrant have not been assigned a D-U-N-S number, the business entity may obtain one directly from Dun & Bradstreet at no cost.
In addition to the D-U-N-S number, FDA also requires facilities to submit an FEI number, which is a unique identifier designated by the Agency to assign, monitor, and track inspections of regulated firms. Organizations that have not previously obtained an FEI number may do so by sending an email request to the Agency.
“FDA requests the name and contact information for the registrant owner and facility information, including name, type of business operation, and contact information. Submitters are also asked to indicate whether they manufacture drugs that are not generic drugs.”
The standards and processes governing self-identification are similar to those of other electronic submissions made to FDA. The Agency states that “self-identification files should be formatted in the same electronic messaging standard used for drug registration and listing information and for the content of labeling for abbreviated new drug applications (ANDAs).” This standard is known as Health Level Seven Structured Product Labeling (SPL), and “allows information to be exchanged, searched, and combined with other data sources in a manner that supports health information technology initiatives to improve patient care.”
GDUFA does not explicitly state any specific penalty for organizations and sites that fail to comply with its self-identification requirement. However, the guidance document states that if a site or organization does fail to comply with the law, it may raise concerns about that site, thus increasing the likelihood of a site inspection prior to approval.
In addition, GDUFA does state that “if a facility fails to self-identify, all FDF or API products manufactured at the facility and all FDFs containing APIs manufactured at the facility will be deemed misbranded.” This is important to note because it is a violation of federal law to ship misbranded products in interstate commerce or to import them into the US, and thus products that are deemed misbranded because of a failure to self-identify may be denied entry into the country.
Are you in the process of developing a generic drug or other FDA-regulated product? Do you manufacture a generic drug in the US? We can help ensure that you are in compliance with these and all other FDA regulations. For additional information about our services and how we can help you, contact us today.
April 5, 2021
After assuring clinical validity, finding and managing the right contract manufacturing organizations (CMOs)/contract development manufacturing organizations (CDMOs) is a Sponsor's major concern when...
August 1, 2016
On September 24, 2013, the FDA published the UDI Rule, which established a standardized identification system for medical devices used in the United States. Under this rule, the label and packages of...
August 18, 2015
On July 19, 2015, Kim Kardashian posted a “selfie” to her Instagram and Twitter accounts. You may be thinking “She does that all the time… Why would that matter to the FDA?” The selfie in question...